Next generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. As a result, their commercial potential is significant; however they are significantly more cost intensive.
As a result, attempts are being made to optimize the workflow to increase antibody yield whilst reducing the development costs.
Download this eBook to explore:
Brought to you by:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
© 2020 Technology Networks
All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy